Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof

Patent metadata

Field	Value
Publication number	US-12366571-B2
Application number	US-202117155642-A
Country	US
Kind code	B2
Filing date	Jan 22, 2021
Priority date	Mar 26, 2014
Publication date	Jul 22, 2025
Grant date	Jul 22, 2025

Abstract

A chemiluminescent detection system, as well as kits and microfluidics devices containing same, are disclosed. Methods of using the system, kits, and devices are also disclosed.

First claim

What is claimed is:

1. A method for detecting the presence and/or concentration of a specific analyte in a sample, comprising the steps of:
(a) combining, either simultaneously or wholly or partially sequentially, components (i), (ii), (iii), (iv), and (v) within a compartment to form a reaction mixture:
(i) a sample suspected of containing the specific analyte;
(ii) a first composition comprising a singlet-oxygen activatable chemiluminescent compound and a first antibody or binding fragment thereof associated therewith, wherein the first antibody or binding fragment thereof is a detection antibody that specifically binds to a first epitope of a specific analyte;
(iii) a second composition comprising a singlet-oxygen activatable chemiluminescent compound and a second antibody or binding fragment thereof associated therewith, wherein the second antibody or binding fragment thereof is a detection antibody that specifically binds to a second epitope of the analyte, and wherein the first and second epitopes at least partially overlap such that the first and second antibodies or binding fragments thereof cannot both bind to a single analyte molecule, and wherein the first and second epitopes are not identical, and wherein the first antibody or binding fragment thereof has a higher affinity for the analyte than the second antibody or binding fragment thereof while the second antibody or fragment thereof has a greater dynamic assay range than the first antibody or fragment thereof, and wherein the singlet-oxygen activatable chemiluminescent compounds of the first and second compositions are different;
(iv) a third composition comprising a third antibody or binding fragment thereof, the third antibody or binding fragment thereof being a capture antibody that specifically binds to a third epitope of the analyte that does not overlap with the first and second epitopes, whereby a single analyte molecule can bind the third antibody or binding fragment thereof and one of the first and second antibodies or binding fragments thereof; and
(v) a sensitizer capable of association with the third antibody or binding fragment thereof, the sensitizer being capable of generating singlet oxygen in its excited state;

(b) allowing the binding of (ii), (iii) and/or (iv) to analyte within the sample, wherein a first sandwich complex comprising an analyte molecule and (ii) and (iv) is formed, and a second sandwich complex comprising another analyte molecule and (iii) and (iv) is formed, and wherein (v) associates with (iv) in the first and second sandwich complexes, thus bringing the sensitizer into close proximity to the chemiluminescent compounds of (ii) and (iii) in the reaction mixture;
(c) activating the sensitizer to generate singlet oxygen, wherein activation of the sensitizer present in the first and second sandwich complexes causes the activation of the chemiluminescent compounds present in the first and second sandwich complexes of the reaction mixture;
(d) determining the amount of chemiluminescence generated by the activated chemiluminescent compounds present in the first and second sandwich complexes of the reaction mixture;
(e) optionally repeating steps (b)-(d); and
(f) detecting the presence and/or concentration of the analyte in the sample by analyzing the amount of chemiluminescence generated by the activated chemiluminescent compounds present in the first and second sandwich complexes in the reaction mixture, wherein the amount of chemiluminescence is directly proportional to the amount of analyte in the sample.

2. The method of claim 1 , wherein the sensitizer is a photosensitizer, and wherein step (c) is further defined as activating the photosensitizer via irradiation with light.

3. The method of claim 2 , further comprising a step of exposing the sample to a separation step prior to combining with any of (ii)-(v).

4. The method of claim 1 , wherein at least one of the first and second compositions further comprises at least one fluorescent molecule that is excited by the activated chemiluminescent compound.

5. The method of claim 4 , further comprising a step of measuring the amount of light emitted by the fluorescent molecules to determine the amount of analyte in the sample.

6. The method of claim 1 , wherein at least one of (ii)-(v) is further defined as being initially provided in the form of a lyophilized reagent, and wherein the method further comprises the step of reconstituting the at least one of (ii)-(v) in an excipient prior to performing step (a).

7. The method of claim 1 , wherein the sample is selected from the group consisting of whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid (CSF), skin, interstitial fluid, tears, mucus, urine, swabs, and combinations thereof.

8. The method of claim 1 , wherein the third antibody or binding fragment thereof is biotinylated, and wherein the sensitizer has streptavidin associated therewith.

9. The method of claim 1 , further comprising a step of diluting the mixture of (i)-(v) prior to step (c).

10. The method of claim 1 , wherein at least one of the first, second, and third antibodies or binding fragments thereof is a polyclonal antibody.

11. The method of claim 1 , wherein at least one of the first, second, and third antibodies or binding fragments thereof is a monoclonal antibody.

12. The method of claim 1 , wherein the analyte is Troponin i.

13. The method of claim 12 , wherein the method detects Troponin I concentrations in a range of from about 0.006 ng/ml to about 60 ng/ml.

14. The method of claim 1 , wherein the first antibody or binding fragment thereof specifically binds to the analyte with a dissociation constant in a range of from about 10 −10 M to about 10 −13 M, and the second antibody or binding fragment thereof specifically binds to the analyte with a dissociation constant in a range of from about 10 −6 M to about 10 −10 M.

15. The method of claim 1 , wherein a combination of the first and second compositions added in step (a) comprises the first composition in a range of from about 5% to about 20% and the second composition in a range of from about 80% to about 95%.

16. The method of claim 1 , wherein the first composition is combined with the sample prior to the second composition.

17. The method of claim 1 , wherein steps (a)-(f) are performed in the same compartment of a microfluidics device.

18. A method for detecting the presence and/or concentration of Troponin I in a sample, comprising the steps of:
(a) combining, either simultaneously or wholly or partially sequentially, components (i), (ii), (iii), (iv), and (v) within a compartment to form a reaction mixture:
(i) a sample suspected of containing Troponin I;
(ii) a first composition comprising a singlet-oxygen activatable chemiluminescent compound and a first monoclonal antibody or binding fragment thereof associated therewith, wherein the first monoclonal antibody or binding fragment thereof is a detection antibody that specifically binds to a first epitope of Troponin I with a dissociation constant in a range of from about 10 −10 M to about 10 −13 M;
(iii) a second composition comprising a singlet-oxygen activatable chemiluminescent compound and a second monoclonal antibody or binding fragment thereof associated therewith, wherein the second monoclonal antibody or binding fragment thereof is a detection antibody that specifically binds to a second epitope of Troponin I with a dissociation constant in a range of from about 10 −6 M to about 10 −10 M, and wherein the first and second epitopes at least partially over

Assignees

• Siemens Healthcare Diagnostics Inc

Inventors

• Li Jay J
• Ledden David J
• Cowden Eric Scott
• Lu Donglai

Classifications

• G01N2800/325

  Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure · CPC title

• G01N2800/32

  Cardiovascular disorders · CPC title

• G01N33/54366

  Apparatus specially adapted for solid-phase testing · CPC title

• G01N33/54306

  Solid-phase reaction mechanisms · CPC title

• G01N33/542

  with steric inhibition or signal modification, e.g. fluorescent quenching · CPC title